Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onyx Walks Away From Option To Develop S*BIO JAK2 Inhibitors; S*BIO CEO Looks To Chart A New Course

This article was originally published in PharmAsia News

Executive Summary

Although anxious to move forward into Phase III trials, Singapore-based S*BIO announced May 4 that partner Onyx Pharmaceuticals will not exercise its options to develop S*BIO's JAK2 inhibitors SB1518 and SB1578. The Singapore biotech has regained full rights to the janus kinase inhibitors and will now look for a new partner to help move forward in development
Advertisement

Related Content

Deals Of The Week Discusses Pharma’s Need For Disruptive Collaboration
CTI Lands Baxter As Pacritinib Partner To Try To Reach Finish Line
Deals Of The Week: Roche/Illumina, GSK/HGSI, Sanofi/MJFF
Singapore's S*BIO Shutters Discovery Operations To Focus On Finding Partners For Lead JAK2 Inhibitor, Interim CEO Says
Death Scare For Pfizer's Pipeline Star Tofacitinib May Be Just A Storm In a Teacup
Novartis/Incyte Move Forward With JAK Inhibitor For MF
JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases
Singapore's S*BIO Expands Collaboration With Onyx On JAK2 Inhibitors
Singapore S*BIO Inks "One Of The Biggest" Biotech Deals in Asia With Onyx For JAK2 Inhibitors
Singapore S*BIO Inks "One Of The Biggest" Biotech Deals in Asia With Onyx For JAK2 Inhibitors
Advertisement
UsernamePublicRestriction

Register

SC078111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel